Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical

by Elisabeth Gludovacz, Kornelia Schuetzenberger, Marlene Resch, Katharina Tillmann, Karin Petroczi, Markus Schosserer, Sigrid Vondra, Serhii Vakal, Gerald Klanert, Jürgen Pollheimer, Tiina A Salminen, Bernd Jilma, Nicole Borth, Thomas Boehm
Published 2021-09-01